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per QALY gained for improved diabetes management for the
program effect lasting for 1 year was $19,573. CONLCUSIONS:
This diabetes management program improved clinical outcomes
for study participants. The results from the cost-effectiveness
analysis reveal that the multifaceted program aimed at increas-
ing the continuity of care for patients with diabetes represents
good value for money.
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OBJECTIVES: Combination therapy, with either repaglinide or
nateglinide in addition to metformin, is typically initiated in
patients with type 2 diabetes unable to achieve glycemic control
with monotherapy. The efﬁcacy and safety of treatment with
these two therapies in combination with metformin has been
evaluated in a head-to-head clinical trial over 16 weeks in type
2 diabetes patients with an inadequate response to sulphonylurea
or metformin alone. The study demonstrated that after 16 weeks
of therapy, patients treated with Repag+Met had lower HbA1c
levels than those treated with Nateg+Met (-1.28% vs -0.67%).
METHODS: A published and peer-reviewed model for type 2
diabetes was used in the analysis to project the impact of treat-
ment with repaglinide and nateglinide, on long-term outcomes
including life expectancy, quality-adjusted life expectancy and
lifetime costs in the Finnish setting. Annual medication costs in
each treatment arm were calculated using the median end of trial
doses. Direct medical costs of treating diabetes-related compli-
cations used in the analysis were collected from published liter-
ature. Outcomes were discounted at 5% annually, in line with
Finnish recommendations. RESULTS: Repaglinide was projected
to increase life expectancy (0.12 years) and quality-adjusted life
expectancy (0.11 years) compared to nateglinide. Lifetime costs
in patients treated with repaglinide were projected to be €2627
lower than nateglinide. Improvements in long-term outcomes
were attributed to a delayed onset of diabetes-related complica-
tions, particularly those associated with retinopathy and
nephropathy. CONCLUSIONS: In combination with metformin,
repaglinide was projected to be dominant to nateglinide, with
improvements in LE, QALE and costs, in the Finnish setting.
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OBJECTIVE: To present the structure and design of a Markov
model intended to determine the cost-effectiveness of the
FreeStyle Navigator™ continuous glucose monitoring system
(NAV) which provides real-time, glucose level readings while
also measuring and displaying the rate and direction of glucose
level changes. The model compares self-monitoring of blood
glucose (SMBG) to the use of NAV in patients with insulin-
requiring Type 1 diabetes who are either trained or untrained in
proper glycemic management, highlighting the ability of each
monitoring device to predict hypoglycemia and hyperglycemia.
METHODS: The model was constructed using probability and
utility values derived from published clinical literature, and sim-
ulates distributions for each monitoring approach into one of ten
diabetic health states. Treatment costs are based on retail prices
and current Medicare reimbursement rates. Cost and effective-
ness values are accumulated monthly over a 36-month period,
yielding incremental cost-effectiveness ratios (ICER) in dollars
per quality-adjusted life month ($/QALM). RESULTS: Model
analysis demonstrates that the use of NAV by a patient trained
in diabetes management is more cost-effective than SMBG.
Although NAV has a higher overall cost of treatment as com-
pared to SMBG ($12,831 v. $8044), it also has a greater effec-
tiveness (57.8QALM v. 44.3QALM), resulting in an ICER of
$355/QALM ($4,269/QALY) for NAV over SMBG. The glucose
level rate of change and trend information provided by the
FreeStyle Navigator™ has been shown to allow appropriately
trained patients to improve upon decisions regarding self-
treatment to better prevent hypo- and hyperglycemic episodes;
resulting in a lower overall treatment cost and higher overall
effectiveness as compared to the use of NAV by an untrained
patient. CONCLUSION: Based on current performance attrib-
utes, a device such as NAV would be more cost-effective than
traditional glucose monitoring options, meeting the willingness-
to-pay threshold of $50,000/QALY commonly used by payers
for the adoption of new technology.
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OBJECTIVES: Clinical evidence suggests that achieving recom-
mended lipid levels reduces the likelihood of CHD events and
mortality. The beneﬁts of statins on LDL-Cholesterol reduction
have been well established, however, improving other lipid para-
meters can contribute to further CHD risk reduction, as low
HDL-C has been shown to be a strong independent risk factor
for CHD. This cost-effectiveness model was developed to deter-
mine the incremental cost of meeting additional recommended
lipid levels when fenoﬁbrate is added to statin therapy in dia-
betic or metabolic syndrome (MS) patients. METHODS: A sim-
ulation model was designed to predict changes in lipid levels
[HDL-C, LDL-C, triglycerides (TG), total cholesterol (TC)] and
associated drug costs based on Wholesale Acquisition Costs over
the course of 1 year. Lipid targets were based on NCEP-ATP III.
A hypothetical cohort of 1000 was modeled for each disease with
abnormal lipid levels based on NHANES data. Comparators for
diabetic patients were atorvastatin and atorvastatin/fenoﬁbrate
combination. Lipid reductions for diabetic patients were based
on the study by Athyros et al. 2002. Comparators for MS were
simvastatin and simvastatin/fenoﬁbrate combination, and lipid
reductions for MS patients were based on the SAFARI trial.
RESULTS: In a cohort of 1000, adding fenoﬁbrate to atorvas-
tatin resulted in 547 more diabetic patients reaching TG targets
and 483 more reaching HDL-C targets. For MS, adding fenoﬁ-
brate to simvastatin resulted in 549 more patients reaching TG
targets, and 288 more reaching HDL targets. 555 more patients
in the diabetic group achieved at least 3 targets while 525 more
MS patients reached at least 3 targets. The 1 year cost per addi-
tional patient reaching three targets was $1848 for diabetics and
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$1954 for MS patients. CONCLUSIONS: Adding fenoﬁbrate to
statin therapy in diabetes and MS increases the number of
patients achieving lipid targets at a relatively small incremental
cost.
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OBJECTIVES: Treating patients to target has been shown to
delay complications of type 2 diabetes mellitus (T2DM). We
developed a model to explore the effectiveness of oral agents in
achieving target levels for HbA1c and lipids in patients with
T2DM. METHODS: The model is broad enough to cover most
relevant comparisons. One analysis considered patients with
T2DM and moderate dyslipidaemia: Triglycerides (TG) of 2.66
+/- 1.77mmol/l and High Density Lipoprotein Cholesterol
(HDL-C) of 1.09 +/- 0.26mmol/l, who had failed
metformin/sulphonylurea therapy. Following UK guidelines,
patients either received rosiglitazone plus a sulphonylurea
(Rosi+SU) or a hypothetical treatment that would simultane-
ously improve HDL, TG and HbA1c by 10%. Patients switched
to insulin if therapy was not tolerated or HbA1c targets not met.
The main outcome measure was Days at Target, deﬁned as the
number of days on which American Diabetic Association target
levels for HbA1c, TG and HDL-C were achieved. The time
horizon considered was 3 years, composed of six month cycles:
long-term diabetic complications were not included. RESULTS:
For Rosi+SU over one year, a cohort of 100 patients would spend
27,854 patient-days at HbA1c target, but only 5,808 patient-
days at combined HbA1c and lipid targets. The increase in Days
at Target per 100 patients treated was 136 for a 10% improve-
ment in TG; 192 for a 10% improvement in HDL; 228 for a
10% improvement in HbA1c, and 667 for improvement in all
three. The model was sensitive to the severity of dyslipidaemia
at baseline. CONCLUSION: The model suggests that existing
agents are more effective at achieving HbA1c control than reach-
ing target lipid levels. Improving HbA1c would provide the
single largest gain in Days at Target, but simultaneous improve-
ment in HbA1c and lipids would be needed to achieve a sub-
stantial gain in diabetes control.
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OBJECTIVES: To project comparative economic and clinical
outcomes associated with treating type 1 diabetes patients on
basal-bolus therapy with insulin glargine (IGlar) or detemir
(IDet), each combined with aspart (IAsp). METHODS: A pub-
lished, peer-reviewed and validated computer simulation model
of diabetes was used to project clinical and cost outcomes over
time horizons of 5, 10, 20, and 35 years. Treatment effect data
were derived from a multicenter, 26 week randomized controlled
trial among subjects with a mean age of 40.2 years and baseline
HbA1c of 8.84% (duration of diabetes: 16.7 years). Equivalent
reduction of HbA1c, the primary endpoint, was observed (NS)
and minor hypoglycemia was parallel (NS), though statistically
signiﬁcant improvements in nocturnal (32% lower; p = 0.046)
and major hypoglycemic episodes (72% lower, p = 0.047; 6.51
vs. 24.5 events per 100 patient years) favored IDet. Costs were
taken from published sources in the US and expressed in 2004
US dollars ($). Clinical and cost outcomes were discounted at
3% per annum. Sensitivity analyses on key input parameters
were performed. RESULTS: Treatment with IDet was associated
with improvements in life expectancy (0.002 to 0.08 years) and
quality-adjusted life expectancy (0.01 to 0.06 QALYs). Direct
medical costs from a US Medicare perspective (pharmacy plus
complication costs) were lower in the IDet group ($672 to
$5174), with the incremental value increasing as the time
horizon lengthened. One-way sensitivity analysis on pharmacy
costs (±15%), discount rate (0–6%), complication costs, and
duration of treatment effect on HbA1c (<5 years) support the
robustness of these ﬁndings. CONCLUSION: Clinical beneﬁts
associated with IDet + IAsp therapy compared to IGlar + IAsp
were projected to improve life expectancy, quality-adjusted life
expectancy and to reduce costs in patients with type 1 diabetes
over a time horizon of 5 to 35 years.
PDB16
BASAL BOLUS THERAPY AMONG TYPE 1 DIABETES
PATIENTS:A COMPARATIVE COST-EFFECTIVENESS ANALYSIS
OF ANALOG- AND HUMAN-BASED INSULIN REGIMENS
Valentine W1, Cobden D2, Palmer A1, Roze S1
1CORE—Center for Outcomes Research, Binningen, Basel,
Switzerland, 2Novo Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: To provide an estimate of the clinical and eco-
nomic outcomes of long-term use of either all analog (insulin
detemir (IDet) + aspart (IAsp)) or all human (NPH + human
soluble insulin (HSI)) basal bolus regimens among type 1 dia-
betes patients. METHODS: Comparative efﬁcacy data was
obtained from a recent 18-week randomized controlled trial (n
= 595) which demonstrated statistically signiﬁcant beneﬁts in
glycemic control (HbA1c: -0.22%, p < 0.001; PPG excursions:
p < 0.001), risk for hypoglycemia (all: 21% lower, p = 0.036;
26.9 vs. 34.6 events per patient year; nocturnal: 55% lower, p <
0.001), and weight gain (-1.01kg, p < 0.001) in favor of analogs.
Subjects were 63% male, aged 39.1 years, and had a mean base-
line HbA1c of 8.38% (duration of diabetes: 15.3 (10.3) years).
A published, peer-reviewed and validated model of type 1 dia-
betes was used to make long-term projections, using second
order Monte Carlo methodology, to evaluate life expectancy,
quality-adjusted life expectancy, cumulative incidence of com-
plications, and direct medical costs (pharmacy plus complication
costs). Base case time horizon was 35 years. Future costs and
clinical beneﬁts were discounted at 3% annually. Sensitivity
analyses were performed. RESULTS: Treatment with IDet+IAsp
was projected to increase life expectancy (0.168 years), QALE
(0.698 QALYs), and reduce cumulative incidences of diabetes-
related comorbidities (cardiovascular, renal, and ocular disease)
versus NPH+HSI. Direct medical costs were higher in the
IDet+IAsp group, leading to an ICER of $14,974 per QALY
gained. One-way sensitivity analysis of pharmacy costs (±15%),
discount rate (0–6%), complication costs, and duration of 
treatment effect on HbA1c (<5 years) support the robustness of
these ﬁndings. CONCLUSION: Patients with type 1 diabetes
who require basal bolus therapy may beneﬁt from analog 
insulin treatment in comparison to human insulin. Long-term
therapy was projected to improve life expectancy, quality-
adjusted life expectancy, and complication rates, representing
good value for money according to commonly supported 
standards.
